Cannabis Law Report

JULY 31, 2019

The New York cannabis market size is expected to reach USD 7.07 billion by 2025, according to a new report by Grand View Research, Inc., Cannabis sales are increasing due to its medical benefits, especially in the treatment of ailments such as chronic pain, mental disorders, and cancer.

Chronic Pain 40

Chronic Pain Epilepsy Treatment Recreational 40

The Joint Blog

NOVEMBER 21, 2022

Cannabis consumption is still a polarizing topic. Indeed, only in the United States, it is projected to hit $16 billion by 2025. And while there are many traditional treatment schemes that you can use, you should also be aware of the impact cannabidiol can have. Pain management . The plant is indeed paradoxical.

Consumption 52

Consumption CBD Research and Development Topical 52

Otherside Farms

SEPTEMBER 13, 2021

Did you know that following the legalization of marijuana in most states, you can now buy or grow cannabis? cannabis industry is projected to reach $30 billion in market value annually by 2025. Not one cannabis strain is the same. What is Cannabis Indica? Effects of Cannabis Indica. Cannabis strain can help.

Indica 52

Indica Sativa Strains Terpenes 52

Cannabis Law Report

JANUARY 5, 2022

The issued claims protect the use of MYMD-1 in a method of treatment for the progressive and generalized loss of skeletal muscle mass and strength known as sarcopenia. MYMD-1 also shows promise in pre-clinical studies as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-proliferation therapeutic.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

OCTOBER 20, 2019

PUBLISHER: CANNABIS LAW REPORT. It is also the first FDA approved drug for the treatment of patients with Dravet syndrome. For example, there is a growing body of evidence that marijuana is working for chronic pain. and Aurora Cannabis, have respective market caps of $5.51 AUTHOR: Judge Mary Celeste (ret).

Marijuana 45

Marijuana Pharmaceutical Chronic Pain Research and Development 45

Cannabis Law Report

NOVEMBER 16, 2021

Our treatment designed for delaying aging has a distinctive drug profile of oral delivery, selectivity, and very low toxicity as compared with TNF blockers, all of which are delivered by injection only. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

SEPTEMBER 13, 2021

Commenting on the size and scope of the market for delaying aging, Dr. Chapman added, “There are no FDA-approved drugs for treating aging disorders and extending healthy lifespan in humans, a market expected to be at least $600 billion by 2025 1 according to a major investment bank.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52